PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of tagLink to Publisher's site
 
Therap Adv Gastroenterol. 2009 July; 2(4 Suppl): 23–30.
PMCID: PMC3002527

Do Patients with Functional Gastrointestinal Disorders have an Altered Gut Flora?

Abstract

The description of the de novo development of irritable bowel syndrome (IBS) following an episode of bacterial gastroenteritis (postinfectious IBS) illustrated the potential for a luminal factor (a bacterial pathogen) to cause this common gastrointestinal ailment. As a consequence of these and other observations as well as results of experiments involving animal models, the enteric flora and the immune response that it generates in the host have, somewhat surprisingly, come centre-stage in IBS research with their potential to induce the pathophysiological changes that are associated with IBS. While evidence for immune dysfunction both in the mucosa and systemically continues to accumulate, methodological limitations have hampered a full delineation of the nature of the microbiota in IBS. The latter is eagerly awaited and may yet provide a firm rationale for the use of certain probiotics and antibiotics in IBS, whose benefits have now been described with some consistency.

Keywords: irritable bowel syndrome, gastroenteritis, probiotics

Introduction

Functional gastrointestinal disorders (FGIDs) are common, of uncertain cause and clinically challenging. Though many persons in the community suffer occasionally or intermittently from FGID-type symptoms, few seek medical attention. Those that do may experience significant impairment to their quality of life as well as incur significant socioeconomic and financial costs. For all of these reasons, significant efforts are now being exerted towards the identification of the cause(s) of FGIDs. Irritable bowel syndrome (IBS), perhaps the best characterized of the FGIDs, has been the subject of considerable and quite diverse research efforts in recent years and this disorder will, therefore, be the focus of this review.

Over the decades, various theories have been advanced to explain the pathogenesis of symptoms in the IBS patient, including dysmotility, visceral hypersensitivity and effects of the psyche. The concept of the gut—brain axis, emphasizing the interactivity at sensory, motor and neuroendocrine levels between the brain and the gut has provided a useful paradigm to encompass these diverse factors. Most recently, as illustrated in Figure 1, this axis has been extended by some to include interaction between the gut flora (or microbiota), the immune system (both mucosal and systemic), the gut and the brain (the gut—brain—immune—microbial axis). In this scenario, interactions between the flora (be it normal or disturbed) and the mucosal immune system (gut-, or mucosa-associated lymphoid tissue, GALT or MALT) lead to the release of peptides and other neuroactive substances which generate, both locally and systemically, the neuromuscular events that typify IBS and generate the patient's symptoms. The advancement of this concept in IBS occurs at a time when considerable emphasis and research effort is being expended with considerable success at understanding the role of the microbiota in health and disease [Guarner and Malagelada, 2003] and in unlocking its therapeutic potential [O'Hara and Shanahan, 2007].

Figure 1.
A schematic representation of how the flora (microbiota), the intestinal epithelium, various components of the immune response (mast cells and lymphocytes) may interact to lead to neural activation and subsequent local and/or systemic responses.

What is the evidence to support such an apparently wild foray into territory previously unexplored or undreamt of in relation to IBS? The evidence comes from a number of sources: postinfectious IBS, data describing various immunological phenomena in IBS (which could be provoked or sustained by microbial stimuli), direct evidence of quantitative and/or qualitative abnormalities in the small intestinal and colonic flora in IBS and therapeutic trials of antibiotics and probiotics in IBS. The latter will be dealt with elsewhere in this issue [Whorwell, 2009] and will not be discussed further in this paper. Let us start with a clinical scenario that has, perhaps, most clearly illustrated the role of the flora and immune responses in a functional disorder: postinfectious IBS (PI-IBS).

Postinfectious IBS

We are now beginning to see real data to directly support the concept of PI-IBS [Spiller, 2003]. First reported by McKendrick and Read [1994] the occurrence of IBS following episodes of bacteriologically confirmed gastroenteritis has now been documented in several studies [Tornblom et al. 2007; Spence and Moss-Morris, 2007; Ruigomez et al. 2007; Thabane et al. 2007; Marshall et al. 2006; Mearin et al. 2005; Dunlop et al. 2003; Spiller et al. 2000; Garcia Rodriguez and Ruigomez, 1999; Gwee et al. 1999,1996; Neal et al. 1997]. Thabane and colleagues concluded that the overall risk for the development of IBS was increased six-fold following an episode of bacterial gastroenteritis with younger subjects, those who have prolonged fever during the episode of gastroenteritis and those who suffer from anxiety or depression being at greatest risk [Thabane et al. 2007]. These symptoms are not transient; in a Scandinavian study in which 12% of their subjects had IBS within 3 months of gastroenteritis, 9% still had symptoms 5 years later [Tornblom et al. 2007]. Neal and colleagues documented similar recovery rates for post-infectious and non-postinfectious IBS in a 6-year follow-up study [Neal et al. 2002].

One study went on to establish a direct link between prior exposure to an infectious agent, persisting low-grade inflammation and IBS [Gwee et al. 1999]. In this study, an increase in the number of chronic inflammatory cells in the rectal mucosa was seen only among those exposed patients who had developed IBS. Others have demonstrated a persisting increase in rectal mucosal enteroendocrine cells, T-lymphocytes and gut permeability in patients with postdysenteric IBS [Dunlop et al. 2003; Spiller et al. 2000]. These observations are important as they indicate a relationship between perturbations of the microbiota, mucosal inflammation and IBS, a hypothesis that is amply supported by data from studies in experimental animal models. The development of IBS has recently been linked with non-GI infections [McKeown et al. 2006], again perhaps invoking a role for a systemic inflammatory response in the mediation of symptoms.

A number of parasites, such as Dientamoeba fragilis, Blastocystis hominis and Giardia have been associated with the development of chronic gastrointestinal symptoms which may mimic IBS [Stark et al. 2007; Grazioli et al. 2006]; whether parasitic infections can trigger IBS, per se, is unknown. Very recently, an outbreak of viral gastroenteritis was associated with the new onset of an IBS-type syndrome in 24% of affected subjects when interviewed 3 months later; subsequent follow-up suggested that postviral IBS was more transient than its bacterial counterpart [Marshall et al. 2007]. Postinfectious IBS may explain only a minority of cases of IBS (1-6.7% in one recent study [Borgaonkar et al. 2006]) but it does represent a clear link between exposure to an environmental agent, inflammation and IBS in predisposed individuals (Figure 2).

Figure 2.
What we have learned from postinfectious irritable bowel syndrome (IBS). Exposure to pathogenic organisms in susceptible individuals leads to a sustained, albeit low-grade, inflammatory response which triggers, through the release of inflammatory mediators ...

Inflammation and IBS

Direct and compelling evidence for a role for mucosal inflammation in IBS was first provided by Chadwick and colleagues among 77 IBS patients: 31 demonstrated microscopic inflammation and eight fulfilled criteria for lymphocytic colitis. However, among the group with ‘normal’ histology, immunohistology revealed increased intraepithelial lymphocytes as well as an increase in CD3+ and CD25+ cells in the lamina propria; all therefore showed evidence of immune activation [Chadwick et al. 2002]. Subsequent studies have provided further evidence of T-lymphocyte [Holmen et al. 2007; Ohman et al. 2005] and mast cell activation [Barbara et al. 2007, 2004; Cenac et al. 2007, Guilarte et al. 2007] in the mucosa in IBS; others have demonstrated an extension of inflammation into the myo-neural compartments [Tornblom et al. 2002] and others still cytokine profiles in peripheral blood mononuclear cells [Liebregts et al. 2007; O'Mahony et al. 2005] and serum [Dinan et al. 2006] compatible with a proinflammatory state.

It is attractive to suggest that these immuno-logical changes could result from exposure to an exogenous (such as bacterial) antigen challenge [Collins, 2002; Spiller, 2002]. That IBS patients may be predisposed to an albeit contained inflammatory response to luminal triggers is, indeed, supported by the finding of polymorphisms in genes that encode for the production of anti-inflammatory cytokines among IBS patients [van der Veek et al. 2005; Gonsalkorale et al. 2003] and by the very recent description of high titers of antiflagellin antibodies in serum derived from IBS patients [Schoepfer et al. 2008; Ivison and Steiner, 2008; Kirsch and Riddell, 2006]. While the idea that IBS patients may truly harbor inflammatory changes in the colonic mucosa is increasingly gaining credence, many important questions remain to be answered and it is clear that this is going to be an area of active investigation for some time to come.

Qualitative or quantitative changes in the enteric flora (microbiota)

For some time, various studies have suggested the presence of qualitative changes in the colonic flora in IBS patients; a relative decrease in the population of bifidobacteria being the most consistent finding [Dear et al. 2005; Malinen et al. 2005; Matto et al. 2005; Si et al. 2004; King et al. 1998; Bradley et al. 1987]. It should be noted, however, that these findings have not always been reproduced and the methods employed have been subject to question. Nevertheless, qualitative changes in the colonic flora, be they primary or secondary, could lead to the proliferation of species that produce more gas [Dear et al. 2005; King et al. 1998] and short-chain fatty acids and are more avid in the decon-jugation of bile acids. With regard to the former the displacement of gas-forming species could result in local changes in gas production, a development which may be poorly tolerated by IBS subjects who seem to have difficulties with the transport of gas along the intestine and to be overly sensitive to gas-induced distension. The latter could, in turn, lead to clinically significant changes in water and electrolyte transport in the colon and affect colonic motility and/or sensitivity. Similarly, a repopulation of the flora with the deficient commensal could restore homeostasis. Attractive as this concept may be, it belies the challenges posed by attempts at a comprehensive description of the flora in IBS, or in any condition.

Several factors limit the interpretability of prior studies, including the unrepresentative nature of the fecal flora, a failure to describe those bacterial populations that may be adherent to the mucosal surface and, above all, the recognition that a very significant proportion of the colonic microbiota cannot be identified by conventional culture methods. Molecular methods are now being applied to this complex issue and have, indeed, confirmed that IBS patients, regardless of sub-type, do exhibit a fecal flora that is clearly different from control subjects [Kassinen et al. 2007; Maukonen et al. 2006; Matto et al. 2005; Malinen et al. 2005]. The precise nature of these differences and their potential to disturb mucosal or myoneural function, in the gut wall, or induce local or systemic immune responses, remains to be defined.

In our own laboratory, we recently investigated the diversity of the dominant microbiota in the fecal material from both IBS patients and healthy controls. In addition we examined mucosal biopsies of nine IBS patients and compared them to their own faecal microbiota. Bacterial DNA was extracted from fecal samples and biopsies, visualized by agarose gel electrophoresis and quantified using spectrophotometry. IBS and healthy fecal samples were compared by DGGE of the V1–V3 region of the 16S rRNA gene. From the analysis of the DGGE profiles for both IBS and healthy subjects we found that the gut microbiota was highly variable but that this variability was far less in biopsies than in faeces among the IBS patients (Figure 3). Statistical comparisons of the fecal analyses indicated that controls exhibited greater variability than the IBS patients.

Figure 3.
Comparisons of molecular profile of colonic microflora from irritable bowel syndrome (IBS) subjects comparing, on the left, samples obtained from mucosal biopsies to those, on the right, obtained from feces. Note, considerably less variability in biopsies ...

More recently, the role of the gut flora in IBS has been taken a stage further with the suggestion that some IBS patients may harbor quantitative changes in the indigenous flora in the small intestine: small intestinal bacterial overgrowth (SIBO) [Cuoco and Salvagnini, 2006; McCallum et al. 2005; Nucera et al. 2005; Pimentel et al. 2003, 2000]. The occurrence of SIBO has been associated with abnormalities in small intestinal motor function [Pimentel et al. 2002] and its eradication with symptomatic relief [Weinstock et al. 2008a, 2008b; Majewski and McCallum, 2007; Esposito et al. 2007; Cuoco and Salvagnini, 2006; Pimentel et al. 2003, 2000]. These striking results have been the target of much criticism on several grounds [Vanner, 2008b; Quigley, 2007; Cuoco et al. 2001; Jones et al. 2001; Mishkin et al. 2001; Riordan et al. 2001; Hasler, 2003]. First, IBS symptoms are nonspecific and may be mimicked by SIBO, regardless of etiology; patient selection is therefore an issue. Second, the hydrogen breath test, which has been the test most widely used to make the diagnosis of SIBO in this context, is subject to considerable error, especially in relation to altered small bowel transit [Vanner, 2008a; Simrén and Stotzer, 2006] and third, others have failed to confirm these finding [Bratten et al. 2008; Posserud et al. 2006; Walters and Vanner, 2005; Parisi et al. 2003].

Efficacy of antibiotics in IBS

The principal evidence for a role for antibiotics in IBS comes from studies among the aforementioned IBS patients with associated SIBO [Majewski and McCallum, 2007; Esposito et al. 2007; Cuoco and Salvagnini, 2006; Pimentel et al. 2003, 2000]. In a subsequent study that did not document bacterial overgrowth, Pimentel and colleagues treated IBS patients with the poorly absorbed antibiotic rifaximin [Pimentel et al. 2006]. Some IBS patients, at least, demonstrated a prolonged response (up to 10 weeks) to a short course of this antibiotic. However, as pointed out in an accompanying editorial, there are several limitations to this study which reduce its impact [Drossman, 2006]. In a recently reported multicenter phase II study, 388 diarrhea-associated IBS subjects were randomized to either rifaximin in a dose of 550mg twice a day or placebo for 14 days, followed by another 14 days on placebo alone and then 12 weeks follow-up. During treatment, at 4 weeks and at 12 weeks, those randomized to rifaximin had a modest 8–13% therapeutic gain for adequate relief of global IBS symptoms and a rather disappointing 4–8% gain for relief of bloating [Lembo et al. 2008; Ringel et al. 2008]. However, the eradication of SIBO, as proposed by these authors, may not be the sole explanation for these responses, which could also be explained on the basis of a suppression of fermenting bacteria in the colon, as suggested by Dear et al. [2005] and supported by the recent report from Sharara et al. [2006]. Finally, one must remain reluctant, pending long-term studies, to recommend a prolonged course of antibiotic therapy to any population regardless of the safety profile of a given antibiotic.

Conclusions

Somewhat surprisingly the enteric flora and the immune response that it generates have come centre-stage in IBS research with their potential to induce the pathophysiological changes that are associated with IBS being most vividly illustrated by postinfectious IBS. While evidence for immune dysfunction both in the mucosa and systemically continues to accumulate, methodological limitations have hampered a full delineation of the nature of the microbiota in IBS. The latter is eagerly awaited and may yet provide a firm rationale for the use of probiotics and antibiotics in IBS.

Conflict of interest statement

None declared.

References

  • Barbara G., Stanghellini V., De Giorgio R., Cremon C., Cottrell G.S., Santini D. et al. (2004) Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 126:693–702 [PubMed]
  • Barbara G., Wang B., Stanghellini V., de Giorgio R., Cremon C., Di Nardo G. et al. (2007) Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology 132:26–37 [PubMed]
  • Borgaonkar M.R., Ford D.C., Marshall J.K., Churchill E., Collins S.M. (2006) The incidence of irritable bowel syndrome among community subjects with previous acute enteric infection. Dig Dis Sci 51:1026–1032 [PubMed]
  • Bradley H.K., Wyatt G.M., Bayliss C.E., Hunter J.O. (1987) Instability in the faecal flora of a patient suffering from food-related irritable bowel syndrome. J Med Microbiol 23:29–32 [PubMed]
  • Bratten J.R., Spanier J., Jones M.P. (2008) Lactulose breath testing does not discriminate patients with irritable bowel syndrome from healthy controls. Am J Gastroenterol 103:958–963 [PubMed]
  • Cenac N., Andrews C.N., Holzhausen M., Chapman K., Cottrell G., Andrade-Gordon P. et al. (2007) Role for protease activity in visceral pain in irritable bowel syndrome. J Clin Invest 117:636–647 [PMC free article] [PubMed]
  • Chadwick V., Chen W., Shu D., Paulus B., Bethwaite P., Tie A. et al. (2002) Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 122:1778–1783 [PubMed]
  • Collins S.M. (2002) A case for an immunological basis for irritable bowel syndrome. Gastroenterology 122:2078–2080 [PubMed]
  • Cuoco L., Cammarota G., Jorizzo R., Gasbarrini G. (2001) Small intestinal bacterial overgrowth and symptoms of irritable bowel syndrome. Am J Gastroenterol 96:2281–2282 [PubMed]
  • Cuoco L., Salvagnini M. (2006) Small intestine bacterial overgrowth in irritable bowel syndrome: a retrospective study with rifaximin. Minerva Gastroenterol Dietol 52:89–95 [PubMed]
  • Dear K.L., Elia M., Hunter J.O. (2005) Do interventions which reduce colonic bacterial fermentation improve symptoms of irritable bowel syndrome?. Dig Dis Sci 50:758–766 [PubMed]
  • Dinan T.G., Quigley E.M., Ahmed S.M., Scully P., O'Brien S., O'Mahony L. et al. (2006) Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker?. Gastroenterology 130:304–311 [PubMed]
  • Drossman D.A. (2006) Treatment for bacterial overgrowth in the irritable bowel syndrome. Ann Intern Med 145:626–628 [PubMed]
  • Dunlop S.P., Jenkins D., Neal K.R., Spiller R.C. (2003) Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology 125:1651–1659 [PubMed]
  • Esposito I., de Leone A., Di Gregorio G., Giaquinto S., de Magistris L., Ferrieri A. et al. (2007) Breath test for differential diagnosis between small intestinal bacterial overgrowth and irritable bowel disease: an observation on non-absorbable antibiotics. World J Gastroenterol 13:6016–6021 [PubMed]
  • Garcia Rodriguez L.A., Ruigomez A. (1999) Increased risk of irritable bowel syndrome after bacterial gastroenteritis: cohort study. Br Med J 318:565–566 [PMC free article] [PubMed]
  • Gonsalkorale W.M., Perrey C., Pravica V., Whorwell P.J., Hutchinson I.V. (2003) Interleukin 10 genotypes in irritable bowel syndrome: evidence for an inflammatory component? Gut 52:91–93 [PMC free article] [PubMed]
  • Grazioli B., Matera G., Laratta C., Schipani G., Guarnieri G., Spiniello E. et al. (2006) Giardia lamblia infection in patients with irritable bowel syndrome and dyspepsia: a prospective study. World J Gastroenterol 12:1941–1944 [PubMed]
  • Guarner F., Malagelada J.R. (2003) Gut flora in health and disease. Lancet 361:512–519 [PubMed]
  • Guilarte M., Santos J., de Torres I., Alonso C., Vicario M., Ramos L. et al. (2007) Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum. Gut 56:203–209 [PMC free article] [PubMed]
  • Gwee K.A., Graham J.C., McKendrick M.W., Collins S.M., Marshall J.S., Walters S.J. et al. (1996) Psychometric scores and persistence of irritable bowel after infectious diarrhoea. Lancet 347:150–153 [PubMed]
  • Gwee K.A., Leong Y.L., Graham C., McKendrick M.W., Collins S.M., Walters S.J. et al. (1999) The role of psychological and biological factors in post-infective gut dysfunction. Gut 44:400–406 [PMC free article] [PubMed]
  • Hasler W.L. (2003) Lactulose breath testing, bacterial overgrowth, and IBS: just a lot of hot air? Gastroenterology 125:1898–1900 [PubMed]
  • Holmen N., Isaksson S., Simren M., Sjovall H., Ohman L. (2007) CD4 CD25 regulatory T cells in irritable bowel syndrome patients. Neurogastroenterol Motil 19:119–125 [PubMed]
  • Ivison S.M., Steiner T.S. (2008) Anti-flagellin antibodies in irritable bowel syndrome: another attack on our commensals!. Neurogastroenterol Motil 20:1081–1085 [PubMed]
  • Jones M.P., Craig R., Olinger E. (2001) Small intestinal bacterial overgrowth is associated with irritable bowel syndrome: the cart lands squarely in front of the horse. Am J Gastroenterol 96:3204–3205 [PubMed]
  • Kassinen A., Krogius-Kurikka L., Makivuokko H., Rinttila T., Paulin L., Corander J. et al. (2007) The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology 133:24–33 [PubMed]
  • King T.S., Elia M., Hunter J.O. (1998) Abnormal colonic fermentation in irritable bowel syndrome. Lancet 352:1187–1189 [PubMed]
  • Kirsch R., Riddell R.H. (2006) Histopathological alterations in irritable bowel syndrome. Mod Pathol 19:1638–1645 [PubMed]
  • Lembo A., Zakko S.F., Ferreira N.L., Ringel Y., Bortey E., Courtney K. et al. (2008) Rifaximin for the treatment of diarrhea-associated irritable bowel syndrome: short-term treatment leading to long term sustained response. Gastroenterology 134:A-545
  • Liebregts T., Adam B., Bredack C., Roth A., Heinzel S., Lester S. et al. (2007) Immune activation in patients with irritable bowel syndrome. Gastroenterology 132:913–920 [PubMed]
  • McCallum R., Schultz C., Sostarich S. (2005) Evaluating the role of small intestinal bacterial overgrowth (SIBO) in diarrhea predominant IBS (IBS-D) patients utilizing the glucose breath test. Gastroenterology 128:T1118
  • McKendrick M.W., Read M.W. (1994) Irritable bowel syndrome - post-salmonella infection. J Infect 29:1–3 [PubMed]
  • McKeown E.S., Parry S.D., Stansfield R., Barton J.R., Welfare M.R. (2006) Postinfectious irritable bowel syndrome may occur after non-gastrointestinal and intestinal infection. Neurogastroenterol Motil 18:839–843 [PubMed]
  • Majewski M., McCallum R.W. (2007) Results of small intestinal bacterial overgrowth testing in irritable bowel syndrome patients: clinical profiles and effects of antibiotic trial. Adv Med Sci 52:139–142 [PubMed]
  • Malinen E., Rinttila T., Kajander K., Mättö J., Kassinen A., Krogius L. et al. (2005) Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am J Gastroenterol 100:373–382 [PubMed]
  • Marshall J.K., Thabane M., Borgaonkar M.R., James C. (2007) Postinfectious irritable bowel syndrome after a food-borne outbreak of acute gastroenteritis attributed to a viral pathogen. Clin Gastroenterol Hepatol 5:457–460 [PubMed]
  • Marshall J.K., Thabane M., Garg A.X., Clark W.F., Salvadori M., Collins S.M. Walkerton Health Study Investigators (2006) Incidence and epidemiology of irritable bowel syndrome after a large waterborne outbreak of bacterial dysentery. Gastroenterology 131:445–450 [PubMed]
  • Matto J., Maunuksela L., Kajander K., Palva A., Korpela R., Kassinen A. et al. (2005) Composition and temporal stability of gastrointestinal microbiota in irritable bowel syndrome - a longitudinal study in IBS and control subjects. FEMS Immunol Med Microbiol 43:213–222 [PubMed]
  • Maukonen J., Satokari R., Matto J., Soderlund H., Mattila-Sandholm T., Saarela M. (2006) Prevalence and temporal stability of selected clostridial groups in irritable bowel syndrome in relation to predominant faecal bacteria. J Med Microbiol 55(Pt 5):625–633 [PubMed]
  • Mearin F., Perez-Oliveras M., Perello A., Vinyet J., Ibaez A., Coderch J. et al. (2005) Dyspepsia and irritable bowel syndrome after a Salmonella gastroenteritis outbreak: one-year follow-up cohort study. Gastroenterology 129:98–104 [PubMed]
  • Mishkin D., Mishkin S. (2001) Pimentel et al. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 96:2505–2506 [PubMed]
  • Neal K.R., Barker L., Spiller R.C. (2002) Prognosis in post-infective irritable bowel syndrome: a six year follow up study. Gut 51:410–413 [PMC free article] [PubMed]
  • Neal K.R., Hebdon J., Spiller R. (1997) Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome. Br Med J 314:779–782 [PMC free article] [PubMed]
  • Nucera G., Gabrielli A., Lupascu A., Lauritano E.C., Santoliquido A., Cremonini F. et al. (2005) Abnormal breath tests to lactose, fructose and sorbitol in irritable bowel syndrome may be explained by small intestinal bacterial overgrowth. Aliment Pharmacol Ther 21:1391–1395 [PubMed]
  • O'Hara A.M., Shanahan F. (2007) Gut micro-biota: mining for therapeutic potential. Clin Gastroenterol Hepatol 5:274–284 [PubMed]
  • Ohman L., Isaksson S., Lundgren A., Simren M., Sjovall H. (2005) A controlled study of colonic immune activity and beta7 blood T lymphocytes in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 3:980–986 [PubMed]
  • O'Mahony L., McCarthy J., Kelly P., Hurley G., Luo F., Chen K. et al. (2005) A randomized, placebo-controlled, double-blind comparison of the probiotic bacteria lactobacillus and bifidobacterium in irritable bowel syndrome (IBS): symptom responses and relationship to cytokine profiles. Gastroenterology 128:541–551 [PubMed]
  • Parisi G., Leandro G., Bottona E., Carrara M., Cardin F., Faedo A. et al. (2003) Small intestinal bacterial overgrowth and irritable bowel syndrome. Am J Gastroenterol 98:2572. [PubMed]
  • Pimentel M., Chow E.J., Lin H.C. (2000) Eradication of small bowel bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 95:3503–3506 [PubMed]
  • Pimentel M., Chow E., Lin H. (2003) Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 98:412–419 [PubMed]
  • Pimentel M., Park S., Mirocha J., Kane S.V., Kong Y. (2006) The effect of a nonabsorbed antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med 145:557–563 [PubMed]
  • Pimentel M., Soffer E.E., Chow E.J., Kong Y., Lin H.C. (2002) Lower frequency of MMC is found in IBS subjects with abnormal lactulose breath test, suggesting bacterial overgrowth. Dig Dis Sci 47:2639–2643 [PubMed]
  • Posserud I., Stotzer P.O., Bjornsson E., Abrahamsson H., Simrén M. (2006) Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut 56:802–808 [PMC free article] [PubMed]
  • Quigley E.M. (2007) A 51-year-old with irritable bowel syndrome: test or treat for bacterial overgrowth? Clin Gastroenterol Hepatol 5:1140–1143 [PubMed]
  • Riordan S.M., McIver C.J., Duncombe V.M., Thomas M.C., Nagree A., Bolin T.D. (2001) Small intestinal bacterial overgrowth and the irritable bowel syndrome. Am J Gastroenterol 96:2506–2508 [PubMed]
  • Ringel Y., Zakko S.F., Ferreira N.L., Bortey E., Wu T., Courtney K. et al. (2008) Predictors of clinical response from a phase 2 multi-center efficacy ctrial using rifaximin, a gut-selective, nonabsorbed antibiotic for the treatment of diarrhea-associated irritable bowel syndrome. Gastroenterology 134:A-550
  • Ruigomez A., Garcia Rodriguez L.A., Panes J. (2007) Risk of irritable bowel syndrome after an episode of bacterial gastroenteritis in general practice: influence of comorbidities. Clin Gastroenterol Hepatol 5:465–469 [PubMed]
  • Schoepfer A.M., Schaffer T., Seibold-Schmid B., Muller S., Seibold F. (2008) Antibodies to flagellin cindicate reactivity to bacterial antigens in IBS patients Neurogastroenterol Motil 20:1110–1118 [PubMed]
  • Sharara A.I., Aoun E., Abdul-Baki H., Mounzer R., Sidani S., Ell-Iajj I. (2006) A randomized doubleblind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol 101:326–333 [PubMed]
  • Si J.M., Yu Y.C., Fan Y.J., Chen S.J. (2004) Intestinal microecology and quality of life in irritable bowel syndrome patients. World J Gastroenterol 10:1802–1805 [PubMed]
  • Simrén M., Stotzer P.-O. (2006) Use and abuse of hydrogen breath tests. Gut 55:297–393 [PMC free article] [PubMed]
  • Spence M.J., Moss-Morris R. (2007) The cognitive behavioural model of irritable bowel syndrome: a prospective investigation of patients with gastroenteritis. Gut 56:1066–1071 [PMC free article] [PubMed]
  • Spiller R.C. (2002) Role of nerves in enteric infection. Gut 51:759–762 [PMC free article] [PubMed]
  • Spiller R.C. (2003) Postinfectious irritable bowel syndrome. Gastroenterology 124:1662–1671 [PubMed]
  • Spiller R.C., Jenkins D., Thornley J.P., Hebden J.M., Wright T., Skinner M. et al. (2000) Increased rectal mucosal enteroendocrine cells T lymphocytes and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 47:804–811 [PMC free article] [PubMed]
  • Stark D., van Hal S., Marriott D., Ellis J., Harkness J. (2007) Irritable bowel syndrome: a review on the role of intestinal protozoa and the importance of their detection and diagnosis. Int J Parasitol 37:11–20 [PubMed]
  • Thabane M., Kottachchi D.T., Marshall J.K. (2007) Systematic review and meta-analysis: the incidence and prognosis of post-infectious irritable bowel syndrome. Aliment Pharmacol Ther 26:535–44 [PubMed]
  • Tornblom H., Holmvall P., Svenungsson B., Lindberg G. (2007) Gastrointestinal symptoms after infectious diarrhea: a five-year follow-up in a Swedish cohort of adults. Clin Gastroenterol Hepatol 5:461–464 [PubMed]
  • Tornblom H., Lindberg G., Nyberg B., Veress B. (2002) Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome. Gastroenterology 123:1972–1979 [PubMed]
  • van der Veek P.P., van den Berg M., de Kroon Y.E., Verspaget H.W., Masclee A.A. (2005) Role of tumor necrosis factor-alpha and interleukin-10 gene polymorphisms in irritable bowel syndrome. Am J Gastroenterol 100:2510–2516 [PubMed]
  • Vanner S. (2008a) The lactulose breath test for diagnosing SIBO in IBS patients: another nail in the coffin. Am J Gastroenterol 103:964–965 [PubMed]
  • Vanner S. (2008b) The small intestinal bacterial overgrowth. Irritable bowel syndrome hypothesis: implications for treatment. Gut 57:1315–1321 [PubMed]
  • Walters B., Vanner S.J. (2005) Detection of bacterial overgrowth in IBS using the lactulose H2 breath test: comparison with 14C-d-Xylose and healthy controls. Am J Gastroenterol 100:1566–1570 [PubMed]
  • Weinstock L.B., Fern S.E., Duntley S.P. (2008a) Restless legs syndrome in patients with irritable bowel syndrome: response to small intestinal bacterial overgrowth therapy. Dig Dis Sci 53:1252–1256 [PubMed]
  • Weinstock L.B., Klutke C.G., Lin H.C. (2008b) Small intestinal bacterial overgrowth in patients with interstitial cystitis and gastrointestinal symptoms. Dig Dis Sci 53:1246–1251 [PubMed]
  • Whorwell P.J. (2009) Do probiotics improve symptoms in patients with irritable bowel syndrome? Ther Adv Gastroenterol 2(Suppl 4):S37–S44 [PMC free article] [PubMed]

Articles from Therapeutic Advances in Gastroenterology are provided here courtesy of SAGE Publications